Sarepta Therapeutics, Inc. (SRPT)
16.01
-0.67
(-4.02%)
USD |
NASDAQ |
Nov 12, 16:00
16.07
+0.06
(+0.37%)
After-Hours: 20:00
Sarepta Therapeutics Enterprise Value : 1.891B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 1.891B |
| November 11, 2026 | 1.963B |
| November 10, 2026 | 1.935B |
| November 09, 2026 | 2.023B |
| November 06, 2026 | 2.085B |
| November 05, 2026 | 2.058B |
| November 04, 2026 | 2.211B |
| November 03, 2026 | 2.162B |
| November 02, 2026 | 2.139B |
| October 30, 2026 | 2.171B |
| October 29, 2026 | 2.236B |
| October 28, 2026 | 2.246B |
| October 27, 2026 | 2.200B |
| October 26, 2026 | 2.102B |
| October 23, 2026 | 2.075B |
| October 22, 2026 | 2.124B |
| October 21, 2026 | 2.164B |
| October 20, 2026 | 2.230B |
| October 19, 2026 | 2.075B |
| October 16, 2026 | 2.008B |
| October 15, 2026 | 2.082B |
| October 14, 2026 | 1.979B |
| October 13, 2026 | 1.945B |
| October 12, 2026 | 2.044B |
| October 09, 2026 | 2.088B |
| Date | Value |
|---|---|
| October 08, 2026 | 2.127B |
| October 07, 2026 | 2.051B |
| October 06, 2026 | 2.030B |
| October 05, 2026 | 2.050B |
| October 02, 2026 | 2.051B |
| October 01, 2026 | 2.058B |
| September 30, 2026 | 2.128B |
| September 29, 2026 | 2.226B |
| September 28, 2026 | 2.243B |
| September 25, 2026 | 2.229B |
| September 24, 2026 | 2.200B |
| September 23, 2026 | 2.259B |
| September 22, 2026 | 2.455B |
| September 21, 2026 | 2.385B |
| September 18, 2026 | 2.381B |
| September 17, 2026 | 2.441B |
| September 16, 2026 | 2.344B |
| September 15, 2026 | 2.446B |
| September 14, 2026 | 2.467B |
| September 11, 2026 | 2.417B |
| September 10, 2026 | 2.425B |
| September 09, 2026 | 2.583B |
| September 08, 2026 | 2.469B |
| September 04, 2026 | 2.634B |
| September 03, 2026 | 2.686B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Beam Therapeutics, Inc. | 1.686B |
| Moderna, Inc. | 92.52B |
| Rocket Pharmaceuticals, Inc. | 2.850M |
| Intellia Therapeutics, Inc. | 1.236B |
| Arrowhead Pharmaceuticals, Inc. | 6.429B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -28.46M |
| Revenue (Quarterly) | 381.35M |
| Total Expenses (Quarterly) | 409.81M |
| EPS Diluted (Quarterly) | -0.2687 |
| Gross Profit Margin (Quarterly) | 49.02% |
| Profit Margin (Quarterly) | -7.46% |
| Earnings Yield | -8.56% |
| Normalized Earnings Yield | -6.865 |